Portfolio Companies News
January 14, 2020Fusion Pharmaceuticals Announces In...
Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB). CPPIB ... read more
January 13, 2020Fusion Pharmaceuticals To Present A...
Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced that Chief Executive Officer John Valliant, Ph.D., will present an overview of the Company... read more
January 9, 2020Aprea Therapeutics to Present at th...
BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief... read more
January 9, 2020Strongbridge Biopharma plc Announce...
~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million ~ ~ Provides Full-Year 2020 KEVEYIS®(dichlorphenamide) Revenue Guidanc... read more
January 8, 2020Targovax and IOVaxis Therapeutics e...
IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 If exercised, the license has a potential value of up to USD 100 million in development and commercial milestones, in addition to double-digi... read more
October 31, 2019Q3 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 114 portfolio companies.
43 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.